TEVA News and Press, Teva Pharmaceutical Industries Limited American Depositary Shares From 06/24/24

2024-06-24 10:07:53 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Teva Pharmaceutical: Buy This Bargain Before It's Gone Teva Pharmaceutical Industries Limited (TEVA) B...

2024-06-20 10:47:04 ET IONQ Inc (IONQ) IONQ is trading DOWN for the last 4 days, and it at trading at $6.96 with volume of 3,028,274 and a one day change of $-0.25 (-3.47%). IONQ Inc has a 52-week low of 4.26 and a 52-week high of $21.60. The business's 50-day moving average price i...

2024-06-15 11:19:01 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Eli Lilly and Company (LLY) Goldman Sac...

2024-06-14 09:55:20 ET More on Corcept Therapeutics, Teva, etc. Corcept Therapeutics Stock Merits Accumulation Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Teva Pharmaceutical: Buy This Bargain Befo...

2024-06-12 12:51:54 ET More on Teva Pharmaceutical Teva Pharmaceutical: Buy This Bargain Before It's Gone Teva wins FDA nod for new Austedo formulation Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) ...

2024-06-11 12:08:45 ET Summary Corcept Therapeutics Incorporated share prices were initially suppressed after a court ruling that Teva's generic version of Korlym would not infringe on its patents. However, the company is preparing an NDA for Korlym's successor, which could be app...

2024-06-11 11:41:04 ET Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024, 08:00 AM ET Company Participants Richard Francis - President & Chief Executive Officer Conference Call Participants ...

2024-06-07 10:57:58 ET Summary Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter o...

2024-06-05 07:00:04 ET Balaji Prasad from Barclays issued a price target of $21.00 for TEVA on 2024-06-05 05:27:00. The adjusted price target was set to $21.00. At the time of the announcement, TEVA was trading at $16.63. The overall price target consensus is at $14.80 w...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45 th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time. To access...